The present invention relates to the field of pulse photometery. More specifically, the invention relates to calculating continuous saturation values using complex number analysis.
Pulse photometry is a noninvasive technique for measuring blood analytes in living tissue. In this technique, multiple light sources emit light of differing wavelengths, which is transmitted through or reflected from a vascular bed. One or more photodetectors then detect the transmitted or reflected light as an optical signal. As the photons propagate through the tissue, they are subjected to random absorption and scattering processes due to the nonhomogeneous nature of the tissue. These effects manifest themselves as a loss of energy in the optical signal, and are generally referred to as bulk loss. In addition to bulk loss, the optical signal is modulated by the flow of arterial blood into the vascular bed. Moreover, the movement of venous blood into or out of the tissue, local tissue compression and local muscle movements super-impose yet another modulation on the optical signal, usually of lower frequency than the arterial flow. For example,
Pulse oximetry is a special case of pulse photometry where the oxygenation of arterial blood is sought in order to estimate the state of oxygen exchange in the body. In order to calculate the oxygen saturation of arterial blood, two wavelengths of light, e.g. Red, at about 660 nm, and Infrared, at about 900 nm, are used to calculate the ratio of two dominant hemoglobin components, oxygenated hemoglobin (HBO2) and deoxygenated hemoglobin (HB). The detected optical signals, which correspond to the Red and Infrared wavelengths, are first normalized in order to balance the effects of unknown source intensity as well as unknown bulk loss at each wavelength. The arterial pulses are then isolated by filtering each normalized signal, where a high pass or a band-pass filter takes advantage of the typically higher frequency of the pulsatile arterial blood, hence the name pulse oximetry. This normalized and filtered signal is referred to as the AC component and is typically sampled with the help of an analog to digital converter with a rate of about 30 to about 100 samples/second. For example,
In order to estimate blood oxygenation, a (Red/Infrared) ratio is calculated by dividing the strength of the Red AC (RdAC) by the corresponding strength of the Infrared AC (IrAC). The (RdAC/IrAC) ratio is then generally plugged into an empirical calibration curve equation that relates it to blood oxygenation. For example, reference can be made to Japanese Patent No. Sho 50/1975-128387, issued to Aoyagi, entitled “Optical Type Blood Measuring Equipment.”
The arterial blood flow generally has a higher fundamental frequency than other components of the photopleth, however, there are cases where the two frequencies may overlap. One such example is the effect of motion artifacts on the optical signal, which is described in detail in U.S. Pat. No 6,157,850, issued to Diab et al., entitled “Signal Processing Apparatus.” Another effect occurs whenever the venous component of the blood is strongly coupled, mechanically, with the arterial component. This condition leads to a venous modulation of the optical signal that has the same or similar frequency as the arterial one. Such conditions are generally difficult to effectively process because of the overlapping effects.
As described in the Aoyagi patent, the strength of each AC waveform may be estimated by measuring its size through, for example, a peak-to-valley subtraction, by a root mean square (RMS) calculations, integrating the area under the waveform, or the like. These calculations are generally least averaged over one or more arterial pulses. It is desirable, however, to calculate instantaneous ratios (RdAC/IrAC) that can be mapped into corresponding instantaneous saturation values, based on the sampling rate of the photopleth. However, such calculations are problematic as the AC signal nears a zero-crossing where the signal to noise ratio (SNR) drops significantly. For example, dividing two signals with low SNR values can render the calculated ratio unreliable, or worse, can render the calculated ratio undefined, such as when a near zero-crossing area causes division by or near zero. To try to avoid division by zero, the Ohmeda Biox pulse oximeter calculated the small changes between consecutive sampling points of each photopleth in order to get instantaneous saturation values.
Note that Ohmeda's differential technique is equivalent to a calculation over a derivative of the photopleth, and the derivative has the same low SNR problem whenever a flattened section of the photopleth is used in the ratios calculations. For example, the derivative will have a zero or near zero value and the RdAC/IrAC ratio will become unreliable or undefined, even in a substantially noise free signal. For example,
Because of some of the foregoing drawbacks associated with the determination of instantaneous or point-by-point saturation from RdAC/IrAC ratios, designers now typically unequally weigh the calculated instantaneous saturation values over each photopleth, even when the photopleth is substantially noise free, with the consequence that a significant number of saturation values receive insignificant weights. This is tantamount to filtering out or ignoring valid signal data during the troublesome sections described above.
The result of the foregoing drawbacks is that the previous attempts fail to determine a stream of point-by-point saturation values. However, it is noteworthy that the sensitivity of the ratio calculation near a zero-crossing section of the waveform is not intrinsic to the photopleth itself, but rather an artifact of passing the detected signal through a high-pass filter. Accordingly, an aspect of the present invention includes a method of determining continuous and reliable calculations of the (RdAC/IrAC) ratio for each sampling point without concern for zero-crossing areas. As discussed in the foregoing and disclosed in the following, such determination of continuous ratios is very advantageous, especially in cases of venous pulsation, intermittent motion artifacts, and the like. Moreover, such determination is advantageous for its sheer diagnostic value.
For purposes of summarizing the invention, certain aspects, advantages and novel features of the invention have been described herein. Of course, it is to be understood that not necessarily all such aspects, advantages or features will be embodied in any particular embodiment of the invention.
A general architecture that implements the various features of the invention will now be described with reference to the drawings. The drawings and the associated descriptions are provided to illustrate embodiments of the invention and not to limit the scope of the invention.
Complex numbers were generally invented/discovered in the 1500's by Galiermo Cardano in Italy as he was struggling to solve a general third order polynomial equation. Later, Argand suggested that each complex number may be represented as a point in a plane where its imaginary part is plotted on the Y-axis and its real part on the X-axis, this is referred to as the Cartesian form of a complex number. An alternate representation of complex numbers is called the polar form where a magnitude and an angle can designate a unique point in the Argand plane, hence representing a complex number. Although mathematicians at that time looked at complex numbers with great suspicion, it turned out that they were useful for the general solutions of polynomial equations and applicable in such diverse fields as quantum mechanics to describe the state of elementary particles.
In the field of electrical engineering, students learn that circuit analysis, under alternating voltage conditions, can be significantly simplified if the concept of complex currents and voltages is introduced. When a voltage is applied to an electrical element, a current is caused to pass through it. Dividing the applied voltage by the corresponding current gives the resistance of the electrical element. In the complex domain, dividing the complex voltage by the complex current give rise to a complex form of resistance called “impedance,” which is represented again by a complex number. The real part of the impedance is the resistance while the complex part is related to capacitance and inductance. The complex part affects the phase, lead or lag, of the driving signals. It can be shown that the response of a linear system to a sinusoidal excitation is a sinusoid with the same frequency but generally of different amplitude and phase. A resistor element, for example, affects the amplitude only, whereas a capacitor or an inductor affects the phase. A combination of resistors, capacitors and/or inductors can affect the amplitude as well as the phase of the driving excitation and are considered examples of a linear system. Since each complex number consists of amplitude and phase, it is natural that they be used to encode the amplitude and phase and track their evolution throughout a linear system. Therefore, when a linear system is driven by a complex excitation, its output will be the same complex input multiplied by a complex scaling factor that scales its amplitude appropriately and adds a certain phase in accordance with the rules of complex multiplication. Note that the phase in this context is a relative one between two fundamental variables of the system, e.g. for an electrical circuit they might be voltage and current at a certain node of the circuit, or output voltage and input voltage, or the like.
In pulse oximetry, there is no direct analog for voltages or currents. Generally, pulse oximetry deals with two highly correlated optical signals, e.g., the Red and Infrared signals, with fundamentally little or no discernible phase difference. Thus, encoding those signals as complex numbers seems to add little or no value to the signal processing. However, there are several conditions under which a variable phase difference may be introduced between the Red and Infrared signals. For example, motion artifacts create a condition where the sensor may decouple from the skin. In such a condition, the detected optical signals will have components that depend on the refraction through the sensor material itself instead of the wavelength of light, as well as the desired components that have traveled through the vascular bed. Venous pulsation creates another condition, which, as disclosed in the foregoing, affects the phase difference. Under the foregoing conditions where the phase is changing, use of complex number encoding provides advantages in signal processing, including providing the ability to continuously monitor the arterial saturation vs. time without concern about signal zero-crossing, as disclosed in the following.
A Hilbert Transformer is a signal processing technique that takes a real signal and converts it into a related signal which has its frequency components shifted by π/2 radians for positive frequencies, and by −π/2 radians for negative frequencies, without affecting their respective amplitudes. The book, “Theory and Application of Digital Signal Processing, Prentice-Hall, Inc.,” by Rabiner and Gold, introduces the subject. Formation of a complex signal is accomplished by considering the original signal itself as the real part of a complex signal and the output of the Hilbert Transformer as the imaginary part of the same complex signal. Such signals are generally referred to as an “analytical signal” in the signal processing field because the magnitudes of its negative frequencies are equal to zero. In the context of pulse photometry, we shall refer to such a complex signal as complex photopleth or complex AC.
It is noteworthy that the prior methodology of seeking a derivative of a signal shifts that signal's components by π/2 radians, similar to the Hilbert transform. However, the derivative of a signal also multiplies each corresponding amplitude by the value of the radian frequency ω, thus magnifying the signal's frequency components as the components increase in frequency. Thus, the derivative is often more sensitive to electronic noise. In contrast, the Hilbert Transformer generally has a flat response with respect to frequency. However, a skilled artisan will recognize other transforms, derivatives, or the like, can be used to encode the imaginary part of the complex photopleth.
When the foregoing complex encoding is applied to both RdAC and IrAC photopleths, as shown in a complex photopleth generator of
Based on the foregoing disclosure, the complex photopleths of
Generating Complex Ratios
For example, when the arterial saturation is constant and type A complex waveforms are generated, the complex ratio plot in the complex plane looks like a fuzzy point very close to the real axis, as shown in
Generating Confidence Measures
Normally, each of the instantaneous complex ratio values are valid and reliable. However, certain physiological or patient motion conditions may render a some or all of the calculated ratios unusable. Therefore, it is desirable to provide confidence measures by which such unreliable points may be discarded, filtered or corrected. Toward that end,
This confidence may be used to gate or preferentially weigh each corresponding complex ratio in a filtering technique to provide more reliable saturation values. For example,
The phase of the instantaneous complex ratios may also be used to assign a confidence measure to each complex ratio value. Typically the phase value should be very close to zero in the case of complex ratios generated from type A complex waveforms, as shown in
Implementing Filtering Techniques
Once the complex waveforms or their corresponding instantaneous complex ratios or saturation values are available, a myriad of linear, nonlinear and statistical filtering techniques may be applied to reliably estimate the blood saturation values. For example, when simple averaging is desired, the areas of the complex photopleth waveforms shown in
Another powerful filtering technique takes advantage of the abundance of ratios values available over short period of time. For example, the continuous stream of instantaneous ratio or saturation values can be fed into a weighing filter along with their associated confidence values. The filter can then discard or appropriately weigh the corresponding value of the ratio or the saturation. The high number of values, e.g., 62.5 values per second in the present embodiment, available to the filter makes it more likely that some of them will be within an acceptable limit despite the affect of disturbances or noise.
Statistical techniques such as frequency distribution analysis can further be used alone or in combination with the previous techniques to estimate the true blood saturation values. Exemplary techniques where the statistics of the distribution of the ratio or saturation values can be used to extract a more accurate estimation of the true saturation value, as disclosed in the following.
Managing Abnormal Waveforms
Under certain physiological conditions, venous blood in the vascular bed may undergo pulsation that may or may not be coupled to the arterial pulsation. These pulsation can be strong enough as to disrupt the normal ratio calculations thus giving erroneous saturation readings. When the arterial pulsation has a distinct frequency from the venous pulsation, then the arterial pulsation can be isolated using frequency analysis such as the Fast Fourier Transform used to perform a Saturation Transform, as disclosed in U.S. Pat. No. 6,157,850, mentioned in the foregoing. Strong venous coupling may not be necessarily uniform in time across each arterial pulse, and under certain patient conditions the venous pulse may affect only a portion on the photopleth. This can be advantageous for an algorithm that analyzes the information in the time domain.
Under such conditions, taking the average value (or determining the area) of all the instantaneous saturation points may not be the best estimate of the true saturation value. For example, the distribution of the instantaneous saturation values of
Managing Motion Artifacts
In the context of pulse oximetry, “motion artifacts” refer to any extraneous disturbing source that affects the shape or quality of the optically detected photopleth signal. The disturbance may be a deformation of the vascular bed, a decoupling of the photo detector from the skin, the movement of the sensor itself along the skin surface, or the like. The wide dynamic range of the effect, in terms of its frequency and size, as well as its multiple sources, makes the impact of motion artifacts on the photopleth quite dramatic. More importantly, the impact of motion artifacts on the calculated saturation values can also be very large, thus causing drawbacks in many older generations of pulse oximeters. For example, when motion is repetitive and affects the photopleth over its entirety, then a combination of adaptive filtering and frequency-domain techniques can provide the best estimates of the saturation values. On the other hand, when motion is intermittent or non-repetitive, e.g. pseudo random, then a combination of a time-domain analysis and adaptive filtering techniques with fast adaptation rates works better. While each of the foregoing techniques has its strength and weaknesses, use of multiple parallel engines executing two or more of the foregoing techniques in parallel, and then fusing their results together, often provides best overall performance. Toward that end, the present technique of complex analysis can be a valuable addition to a set of parallel engines that advantageously improves the accuracy of pulse oximeters by correcting for a subset of conditions where the previous algorithms have failed. For example, the ability of the present algorithm to explicitly encode the phase of the signal on a point by point basis renders it very valuable in case of sensor decoupling from the skin where phase decorrelation between Red and Infrared photopleths is prevalent.
At the outset, it is difficult to tell which ratios of
Using Frequency Domain Complex Ratios
When a real signal is transformed into the frequency domain, using the Fourier transform for example, the corresponding frequency representation is a series of complex numbers. These complex numbers denote complex frequencies each having a magnitude and a phase. When the Red and Infrared photopleths are transformed into the frequency domain, their corresponding complex frequencies can advantageously be divided to generate complex ratios. Each complex ratio posses a magnitude and a phase similar to the complex ratios generated in the time domain, as disclosed in the foregoing. The frequency domain complex ratios are a representation that has complex ratios vs. frequency, as opposed to representations that have time domain complex ratios vs. time. As disclosed, each technique has its advantages and disadvantages depending on the type of signals present and the nature of the perturbations.
An example of the use of frequency domain complex ratios according to aspects of the present invention are illustrated in
Although the foregoing disclosure generally references various signal processing mechanisms, a skilled artisan will recognize from the disclosure herein that the generators 500, 800, 1100, and 1500 can be implemented with software, firmware, or the like executing on hardware, such as, for example a digital signal processor (DSP). Moreover, the calculations incorporated into the generators can be carried out using software, hardware, or combinations of the same. In addition, the DSP can be part of a portable or stationary device, such as an oximeter, personal monitoring device, or the like.
Although the foregoing invention has been described in terms of certain preferred embodiments, other embodiments will be apparent to those of ordinary skill in the art from the disclosure herein. Additionally, other combinations, omissions, substitutions and modifications will be apparent to the skilled artisan in view of the disclosure herein. Accordingly, the present invention is not intended to be limited by the reaction of the preferred embodiments, but is to be defined by reference to the appended claims.
Additionally, all publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application was specifically and individually indicated to be incorporated by reference.
The present application claims priority benefit under 35 U.S.C. §120 to, and is a continuation of, U.S. patent application Ser. No. 13/896,731, filed May 17, 2013, entitled “Systems and Methods for Determining Blood Oxygen Saturation Values Using Complex Number Encoding,” which is a continuation of U.S. patent application Ser. No. 12/248,868, filed Oct. 9, 2008, now U.S. Pat. No. 8,447,374, entitled “Systems and Methods for Determining Blood Oxygen Saturation Values Using Complex Number Encoding,” which is a continuation of U.S. patent application Ser. No. 11/288,812, filed Nov. 28, 2005, now U.S. Pat. No. 7,440,787, entitled “Systems and Methods for Determining Blood Oxygen Saturation Values Using Complex Number Encoding,” which is a continuation of U.S. patent application Ser. No. 10/727,348, filed Dec. 3, 2003, now U.S. Pat. No. 6,970,792, entitled “Systems and Methods for Determining Blood Oxygen Saturation Values Using Complex Number Encoding,” which claims priority benefit under 35 U.S.C. §119(e) from U.S. Provisional Application No. 60/430,834, filed Dec. 4, 2002, entitled “Systems and Methods for Determining Blood Oxygen Saturation Values Using Complex Number Encoding.” The present application hereby incorporates the foregoing disclosures herein by reference in their entirety.
Number | Name | Date | Kind |
---|---|---|---|
4051522 | Healy | Sep 1977 | A |
4085378 | Ryan | Apr 1978 | A |
4623248 | Sperinde | Nov 1986 | A |
4653498 | New | Mar 1987 | A |
4745398 | Abel | May 1988 | A |
4765340 | Sakai | Aug 1988 | A |
4800495 | Smith | Jan 1989 | A |
4802486 | Goodman | Feb 1989 | A |
4863265 | Flower | Sep 1989 | A |
4870588 | Merhav | Sep 1989 | A |
4911167 | Corenman | Mar 1990 | A |
4934372 | Corenman et al. | Jun 1990 | A |
4942877 | Sakai | Jul 1990 | A |
4955379 | Hall | Sep 1990 | A |
4960128 | Gordon et al. | Oct 1990 | A |
4964408 | Hink et al. | Oct 1990 | A |
4965840 | Subbarao | Oct 1990 | A |
5003252 | Nystrom | Mar 1991 | A |
RE33643 | Isaacson et al. | Jul 1991 | E |
5041187 | Hink et al. | Aug 1991 | A |
5069213 | Polczynski | Dec 1991 | A |
5163438 | Gordon et al. | Nov 1992 | A |
5170791 | Boos et al. | Dec 1992 | A |
5188108 | Secker | Feb 1993 | A |
5190038 | Polson | Mar 1993 | A |
5193124 | Subbarao | Mar 1993 | A |
5218962 | Mannheimer | Jun 1993 | A |
5226417 | Swedlow | Jul 1993 | A |
5246002 | Prosser | Sep 1993 | A |
5259381 | Cheung | Nov 1993 | A |
5270942 | Reed | Dec 1993 | A |
5307284 | Brunfeldt et al. | Apr 1994 | A |
5319355 | Russek | Jun 1994 | A |
5331394 | Shalon et al. | Jul 1994 | A |
5337744 | Branigan | Aug 1994 | A |
5341805 | Stavridi et al. | Aug 1994 | A |
5345510 | Singhi | Sep 1994 | A |
5353356 | Waugh et al. | Oct 1994 | A |
5355882 | Ukawa | Oct 1994 | A |
5357965 | Hall et al. | Oct 1994 | A |
5368224 | Richardson | Nov 1994 | A |
D353195 | Savage et al. | Dec 1994 | S |
D353196 | Savage et al. | Dec 1994 | S |
5377676 | Vari et al. | Jan 1995 | A |
5384451 | Smith et al. | Jan 1995 | A |
5398003 | Heyl et al. | Mar 1995 | A |
5404003 | Smith | Apr 1995 | A |
5406952 | Barnes | Apr 1995 | A |
D359546 | Savage et al. | Jun 1995 | S |
5421329 | Casciani | Jun 1995 | A |
5431170 | Mathews | Jul 1995 | A |
D361840 | Savage et al. | Aug 1995 | S |
5438983 | Falcone | Aug 1995 | A |
5442940 | Secker | Aug 1995 | A |
5445156 | Daft | Aug 1995 | A |
D362063 | Savage et al. | Sep 1995 | S |
5448991 | Polson et al. | Sep 1995 | A |
5452717 | Branigan et al. | Sep 1995 | A |
D363120 | Savage et al. | Oct 1995 | S |
5456252 | Vari et al. | Oct 1995 | A |
5479934 | Imran | Jan 1996 | A |
5481620 | Vaidyanathan | Jan 1996 | A |
5482036 | Diab et al. | Jan 1996 | A |
5490505 | Diab et al. | Feb 1996 | A |
5494043 | O'Sullivan et al. | Feb 1996 | A |
5503148 | Pologe | Apr 1996 | A |
5533511 | Kaspari et al. | Jul 1996 | A |
5534851 | Russek | Jul 1996 | A |
5542421 | Erdman | Aug 1996 | A |
5549111 | Wright et al. | Aug 1996 | A |
5561275 | Savage et al. | Oct 1996 | A |
5562002 | Lalin | Oct 1996 | A |
5575284 | Athan | Nov 1996 | A |
5588435 | Weng et al. | Dec 1996 | A |
5590649 | Caro et al. | Jan 1997 | A |
5602924 | Durand et al. | Feb 1997 | A |
5608820 | Vaidyanathan | Mar 1997 | A |
5610996 | Eller | Mar 1997 | A |
5632272 | Diab et al. | May 1997 | A |
5638816 | Kiani-Azarbayjany et al. | Jun 1997 | A |
5638818 | Diab et al. | Jun 1997 | A |
5645440 | Tobler et al. | Jul 1997 | A |
5652566 | Lambert | Jul 1997 | A |
5685299 | Diab et al. | Nov 1997 | A |
5720293 | Quinn | Feb 1998 | A |
D393830 | Tobler et al. | Apr 1998 | S |
5743262 | Lepper, Jr. et al. | Apr 1998 | A |
5758644 | Diab et al. | Jun 1998 | A |
5760910 | Lepper, Jr. et al. | Jun 1998 | A |
5769785 | Diab et al. | Jun 1998 | A |
5782237 | Casciani | Jul 1998 | A |
5782757 | Diab et al. | Jul 1998 | A |
5785659 | Caro et al. | Jul 1998 | A |
5791347 | Flaherty et al. | Aug 1998 | A |
5810734 | Caro et al. | Sep 1998 | A |
5820267 | Baker, Jr. et al. | Oct 1998 | A |
5823950 | Diab et al. | Oct 1998 | A |
5830131 | Caro et al. | Nov 1998 | A |
5833618 | Caro et al. | Nov 1998 | A |
5842979 | Jarman | Dec 1998 | A |
5853364 | Baker, Jr. et al. | Dec 1998 | A |
5860919 | Kiani-Azarbayjany et al. | Jan 1999 | A |
5865736 | Baker, Jr. et al. | Feb 1999 | A |
5890929 | Mills et al. | Apr 1999 | A |
5891023 | Lynn | Apr 1999 | A |
5904654 | Wohltmann et al. | May 1999 | A |
5919134 | Diab | Jul 1999 | A |
5921921 | Potratz et al. | Jul 1999 | A |
5934925 | Tobler et al. | Aug 1999 | A |
5940182 | Lepper, Jr. et al. | Aug 1999 | A |
5950139 | Korycan | Sep 1999 | A |
5987343 | Kinast | Nov 1999 | A |
5995855 | Kiani et al. | Nov 1999 | A |
5997343 | Mills et al. | Dec 1999 | A |
6002952 | Diab et al. | Dec 1999 | A |
6011986 | Diab et al. | Jan 2000 | A |
6027452 | Flaherty et al. | Feb 2000 | A |
6036642 | Diab et al. | Mar 2000 | A |
6045509 | Caro et al. | Apr 2000 | A |
6047203 | Sackner et al. | Apr 2000 | A |
6064910 | Andersson et al. | May 2000 | A |
6067462 | Diab et al. | May 2000 | A |
6081735 | Diab et al. | Jun 2000 | A |
6083172 | Baker, Jr. et al. | Jul 2000 | A |
6088607 | Diab et al. | Jul 2000 | A |
6110522 | Lepper, Jr. et al. | Aug 2000 | A |
6119026 | McNulty et al. | Sep 2000 | A |
6122535 | Kaestle et al. | Sep 2000 | A |
6124597 | Shehada | Sep 2000 | A |
6128521 | Marro et al. | Oct 2000 | A |
6129675 | Jay | Oct 2000 | A |
6135952 | Coetzee | Oct 2000 | A |
6144868 | Parker | Nov 2000 | A |
6151516 | Kiani-Azarbayjany et al. | Nov 2000 | A |
6152754 | Gerhardt et al. | Nov 2000 | A |
6157850 | Diab et al. | Dec 2000 | A |
6165005 | Mills et al. | Dec 2000 | A |
6184521 | Coffin, IV et al. | Feb 2001 | B1 |
6188407 | Smith et al. | Feb 2001 | B1 |
6206830 | Diab et al. | Mar 2001 | B1 |
6229856 | Diab et al. | May 2001 | B1 |
6232609 | Snyder et al. | May 2001 | B1 |
6236872 | Diab et al. | May 2001 | B1 |
6241683 | Macklem et al. | Jun 2001 | B1 |
6253097 | Aronow et al. | Jun 2001 | B1 |
6256523 | Diab et al. | Jul 2001 | B1 |
6263222 | Diab et al. | Jul 2001 | B1 |
6278522 | Lepper, Jr. et al. | Aug 2001 | B1 |
6280213 | Tobler et al. | Aug 2001 | B1 |
6285896 | Tobler et al. | Sep 2001 | B1 |
6301493 | Marro et al. | Oct 2001 | B1 |
6317627 | Ennen et al. | Nov 2001 | B1 |
6321100 | Parker | Nov 2001 | B1 |
6325761 | Jay | Dec 2001 | B1 |
6334065 | Al-Ali et al. | Dec 2001 | B1 |
6343224 | Parker | Jan 2002 | B1 |
6349228 | Kiani et al. | Feb 2002 | B1 |
6360114 | Diab et al. | Mar 2002 | B1 |
6368283 | Xu et al. | Apr 2002 | B1 |
6371921 | Caro et al. | Apr 2002 | B1 |
6377829 | Al-Ali | Apr 2002 | B1 |
6388240 | Schulz et al. | May 2002 | B2 |
6397091 | Diab et al. | May 2002 | B2 |
6430437 | Marro | Aug 2002 | B1 |
6430525 | Weber et al. | Aug 2002 | B1 |
6463311 | Diab | Oct 2002 | B1 |
6470199 | Kopotic et al. | Oct 2002 | B1 |
6501975 | Diab et al. | Dec 2002 | B2 |
6505059 | Kollias et al. | Jan 2003 | B1 |
6515273 | Al-Ali | Feb 2003 | B2 |
6519486 | Edgar, Jr. et al. | Feb 2003 | B1 |
6519487 | Parker | Feb 2003 | B1 |
6525386 | Mills et al. | Feb 2003 | B1 |
6526300 | Kiani et al. | Feb 2003 | B1 |
6541756 | Schulz et al. | Apr 2003 | B2 |
6542764 | Al-Ali et al. | Apr 2003 | B1 |
6580086 | Schulz et al. | Jun 2003 | B1 |
6584336 | Ali et al. | Jun 2003 | B1 |
6595316 | Cybulski et al. | Jul 2003 | B2 |
6597932 | Tian et al. | Jul 2003 | B2 |
6597933 | Kiani et al. | Jul 2003 | B2 |
6606511 | Ali et al. | Aug 2003 | B1 |
6632181 | Flaherty et al. | Oct 2003 | B2 |
6639668 | Trepagnier | Oct 2003 | B1 |
6640116 | Diab | Oct 2003 | B2 |
6643530 | Diab et al. | Nov 2003 | B2 |
6650917 | Diab et al. | Nov 2003 | B2 |
6654624 | Diab et al. | Nov 2003 | B2 |
6658276 | Kianl et al. | Dec 2003 | B2 |
6661161 | Lanzo et al. | Dec 2003 | B1 |
6671531 | Al-Ali et al. | Dec 2003 | B2 |
6678543 | Diab et al. | Jan 2004 | B2 |
6684090 | Ali et al. | Jan 2004 | B2 |
6684091 | Parker | Jan 2004 | B2 |
6697656 | Al-Ali | Feb 2004 | B1 |
6697657 | Shehada et al. | Feb 2004 | B1 |
6697658 | Al-Ali | Feb 2004 | B2 |
RE38476 | Diab et al. | Mar 2004 | E |
6699194 | Diab et al. | Mar 2004 | B1 |
6714804 | Al-Ali et al. | Mar 2004 | B2 |
RE38492 | Diab et al. | Apr 2004 | E |
6721582 | Trepagnier et al. | Apr 2004 | B2 |
6721585 | Parker | Apr 2004 | B1 |
6725075 | Al-Ali | Apr 2004 | B2 |
6728560 | Kollias et al. | Apr 2004 | B2 |
6735459 | Parker | May 2004 | B2 |
6745060 | Diab et al. | Jun 2004 | B2 |
6760607 | Al-Ali | Jul 2004 | B2 |
6770028 | Ali et al. | Aug 2004 | B1 |
6771994 | Kiani et al. | Aug 2004 | B2 |
6792300 | Diab et al. | Sep 2004 | B1 |
6813511 | Diab et al. | Nov 2004 | B2 |
6816741 | Diab | Nov 2004 | B2 |
6822564 | Al-Ali | Nov 2004 | B2 |
6826419 | Diab et al. | Nov 2004 | B2 |
6830711 | Mills et al. | Dec 2004 | B2 |
6850787 | Weber et al. | Feb 2005 | B2 |
6850788 | Al-Ali | Feb 2005 | B2 |
6852083 | Caro et al. | Feb 2005 | B2 |
6861639 | Al-Ali | Mar 2005 | B2 |
6898452 | Al-Ali et al. | May 2005 | B2 |
6920345 | Al-Ali et al. | Jul 2005 | B2 |
6931268 | Kiani-Azarbayjany et al. | Aug 2005 | B1 |
6934570 | Kiani et al. | Aug 2005 | B2 |
6939305 | Flaherty et al. | Sep 2005 | B2 |
6943348 | Coffin, IV | Sep 2005 | B1 |
6950687 | Al-Ali | Sep 2005 | B2 |
6961598 | Diab | Nov 2005 | B2 |
6970792 | Diab | Nov 2005 | B1 |
6979812 | Al-Ali | Dec 2005 | B2 |
6985764 | Mason et al. | Jan 2006 | B2 |
6993371 | Kiani et al. | Jan 2006 | B2 |
6996427 | Ali et al. | Feb 2006 | B2 |
6999904 | Weber et al. | Feb 2006 | B2 |
7003338 | Weber et al. | Feb 2006 | B2 |
7003339 | Diab et al. | Feb 2006 | B2 |
7015451 | Dalke et al. | Mar 2006 | B2 |
7024233 | Ali et al. | Apr 2006 | B2 |
7027849 | Al-Ali | Apr 2006 | B2 |
7030749 | Al-Ali | Apr 2006 | B2 |
7039449 | Al-Ali | May 2006 | B2 |
7041060 | Flaherty et al. | May 2006 | B2 |
7044918 | Diab | May 2006 | B2 |
7067893 | Mills et al. | Jun 2006 | B2 |
7096052 | Mason et al. | Aug 2006 | B2 |
7096054 | Abdul-Hafiz et al. | Aug 2006 | B2 |
7132641 | Schulz et al. | Nov 2006 | B2 |
7142901 | Kiani et al. | Nov 2006 | B2 |
7149561 | Diab | Dec 2006 | B2 |
7186966 | Al-Ali | Mar 2007 | B2 |
7190261 | Al-Ali | Mar 2007 | B2 |
7215984 | Diab | May 2007 | B2 |
7215986 | Diab | May 2007 | B2 |
7221971 | Diab | May 2007 | B2 |
7225006 | Al-Ali et al. | May 2007 | B2 |
7225007 | Al-Ali | May 2007 | B2 |
RE39672 | Shehada et al. | Jun 2007 | E |
7239905 | Kiani-Azarbayjany et al. | Jul 2007 | B2 |
7245953 | Parker | Jul 2007 | B1 |
7254429 | Schurman et al. | Aug 2007 | B2 |
7254431 | Al-Ali | Aug 2007 | B2 |
7254433 | Diab et al. | Aug 2007 | B2 |
7254434 | Schulz et al. | Aug 2007 | B2 |
7272425 | Al-Ali | Sep 2007 | B2 |
7274955 | Kiani et al. | Sep 2007 | B2 |
D554263 | Al-Ali | Oct 2007 | S |
7280858 | Al-Ali et al. | Oct 2007 | B2 |
7289835 | Mansfield et al. | Oct 2007 | B2 |
7292883 | De Felice et al. | Nov 2007 | B2 |
7295866 | Al-Ali | Nov 2007 | B2 |
7328053 | Diab et al. | Feb 2008 | B1 |
7332784 | Mills et al. | Feb 2008 | B2 |
7340287 | Mason et al. | Mar 2008 | B2 |
7341559 | Schulz et al. | Mar 2008 | B2 |
7343186 | Lamego et al. | Mar 2008 | B2 |
D566282 | Al-Ali et al. | Apr 2008 | S |
7355512 | Al-Ali | Apr 2008 | B1 |
7356365 | Schurman | Apr 2008 | B2 |
7371981 | Abdul-Hafiz | May 2008 | B2 |
7373193 | Al-Ali et al. | May 2008 | B2 |
7373194 | Weber et al. | May 2008 | B2 |
7376453 | Diab et al. | May 2008 | B1 |
7377794 | Al-Ali et al. | May 2008 | B2 |
7377899 | Weber et al. | May 2008 | B2 |
7383070 | Diab et al. | Jun 2008 | B2 |
7415297 | Al-Ali et al. | Aug 2008 | B2 |
7428432 | Ali et al. | Sep 2008 | B2 |
7438683 | Al-Ali et al. | Oct 2008 | B2 |
7440787 | Diab | Oct 2008 | B2 |
7454240 | Diab et al. | Nov 2008 | B2 |
7467002 | Weber et al. | Dec 2008 | B2 |
7469157 | Diab et al. | Dec 2008 | B2 |
7471969 | Diab et al. | Dec 2008 | B2 |
7471971 | Diab et al. | Dec 2008 | B2 |
7483729 | Al-Ali et al. | Jan 2009 | B2 |
7483730 | Diab et al. | Jan 2009 | B2 |
7489958 | Diab et al. | Feb 2009 | B2 |
7496391 | Diab et al. | Feb 2009 | B2 |
7496393 | Diab et al. | Feb 2009 | B2 |
D587657 | Al-Ali et al. | Mar 2009 | S |
7499741 | Diab et al. | Mar 2009 | B2 |
7499835 | Weber et al. | Mar 2009 | B2 |
7500950 | Al-Ali et al. | Mar 2009 | B2 |
7509154 | Diab et al. | Mar 2009 | B2 |
7509494 | Al-Ali | Mar 2009 | B2 |
7510849 | Schurman et al. | Mar 2009 | B2 |
7526328 | Diab et al. | Apr 2009 | B2 |
7530942 | Diab | May 2009 | B1 |
7530949 | Al Ali et al. | May 2009 | B2 |
7530955 | Diab et al. | May 2009 | B2 |
7563110 | Al-Ali et al. | Jul 2009 | B2 |
7596398 | Al-Ali et al. | Sep 2009 | B2 |
7618375 | Flaherty | Nov 2009 | B2 |
D606659 | Kiani et al. | Dec 2009 | S |
7647083 | Al-Ali et al. | Jan 2010 | B2 |
D609193 | Al-Ali et al. | Feb 2010 | S |
D614305 | Al-Ali et al. | Apr 2010 | S |
RE41317 | Parker | May 2010 | E |
7729733 | Al-Ali et al. | Jun 2010 | B2 |
7734320 | Al-Ali | Jun 2010 | B2 |
7761127 | Al-Ali et al. | Jul 2010 | B2 |
7761128 | Al-Ali et al. | Jul 2010 | B2 |
7764982 | Dalke et al. | Jul 2010 | B2 |
D621516 | Kiani et al. | Aug 2010 | S |
7791155 | Diab | Sep 2010 | B2 |
7801581 | Diab | Sep 2010 | B2 |
7822452 | Schurman et al. | Oct 2010 | B2 |
RE41912 | Parker | Nov 2010 | E |
7844313 | Kiani et al. | Nov 2010 | B2 |
7844314 | Al-Ali | Nov 2010 | B2 |
7844315 | Al-Ali | Nov 2010 | B2 |
7865222 | Weber et al. | Jan 2011 | B2 |
7873497 | Weber et al. | Jan 2011 | B2 |
7880606 | Al-Ali | Feb 2011 | B2 |
7880626 | Al-Ali et al. | Feb 2011 | B2 |
7891355 | Al-Ali et al. | Feb 2011 | B2 |
7894868 | Al-Ali et al. | Feb 2011 | B2 |
7899507 | Al-Ali et al. | Mar 2011 | B2 |
7899518 | Trepagnier et al. | Mar 2011 | B2 |
7904132 | Weber et al. | Mar 2011 | B2 |
7909772 | Popov et al. | Mar 2011 | B2 |
7910875 | Al-Ali | Mar 2011 | B2 |
7919713 | Al-Ali et al. | Apr 2011 | B2 |
7937128 | Al-Ali | May 2011 | B2 |
7937129 | Mason et al. | May 2011 | B2 |
7937130 | Diab et al. | May 2011 | B2 |
7941199 | Kiani | May 2011 | B2 |
7951086 | Flaherty et al. | May 2011 | B2 |
7957780 | Lamego et al. | Jun 2011 | B2 |
7962188 | Kiani et al. | Jun 2011 | B2 |
7962190 | Diab et al. | Jun 2011 | B1 |
7976472 | Kiani | Jul 2011 | B2 |
7988637 | Diab | Aug 2011 | B2 |
7990382 | Kiani | Aug 2011 | B2 |
7991446 | Al-Ali et al. | Aug 2011 | B2 |
8000761 | Al-Ali | Aug 2011 | B2 |
8008088 | Bellott et al. | Aug 2011 | B2 |
RE42753 | Kiani-Azarbayjany et al. | Sep 2011 | E |
8019400 | Diab et al. | Sep 2011 | B2 |
8028701 | Al-Ali et al. | Oct 2011 | B2 |
8029765 | Bellott et al. | Oct 2011 | B2 |
8036728 | Diab et al. | Oct 2011 | B2 |
8046040 | Ali et al. | Oct 2011 | B2 |
8046041 | Diab et al. | Oct 2011 | B2 |
8046042 | Diab et al. | Oct 2011 | B2 |
8048040 | Kiani | Nov 2011 | B2 |
8050728 | Al-Ali et al. | Nov 2011 | B2 |
RE43169 | Parker | Feb 2012 | E |
8118620 | Al-Ali et al. | Feb 2012 | B2 |
8126528 | Diab et al. | Feb 2012 | B2 |
8128572 | Diab et al. | Mar 2012 | B2 |
8130105 | Al-Ali et al. | Mar 2012 | B2 |
8145287 | Diab et al. | Mar 2012 | B2 |
8150487 | Diab et al. | Apr 2012 | B2 |
8175672 | Parker | May 2012 | B2 |
8180420 | Diab et al. | May 2012 | B2 |
8182443 | Kiani | May 2012 | B1 |
8185180 | Diab et al. | May 2012 | B2 |
8190223 | Al-Ali et al. | May 2012 | B2 |
8190227 | Diab et al. | May 2012 | B2 |
8203438 | Kiani et al. | Jun 2012 | B2 |
8203704 | Merritt et al. | Jun 2012 | B2 |
8224411 | Al-Ali et al. | Jul 2012 | B2 |
8228181 | Al-Ali | Jul 2012 | B2 |
8229533 | Diab et al. | Jul 2012 | B2 |
8233955 | Al-Ali et al. | Jul 2012 | B2 |
8244325 | Al-Ali et al. | Aug 2012 | B2 |
8255026 | Al-Ali | Aug 2012 | B1 |
8255027 | Al-Ali et al. | Aug 2012 | B2 |
8255028 | Al-Ali et al. | Aug 2012 | B2 |
8260577 | Weber et al. | Sep 2012 | B2 |
8265723 | McHale et al. | Sep 2012 | B1 |
8274360 | Sampath et al. | Sep 2012 | B2 |
8301217 | Al-Ali et al. | Oct 2012 | B2 |
8310336 | Muhsin et al. | Nov 2012 | B2 |
8315683 | Al-Ali et al. | Nov 2012 | B2 |
RE43860 | Parker | Dec 2012 | E |
8337403 | Al-Ali et al. | Dec 2012 | B2 |
6970792 | Diab | Jan 2013 | C1 |
8346330 | Lamego | Jan 2013 | B2 |
8353842 | Al-Ali et al. | Jan 2013 | B2 |
8355766 | MacNeish, III et al. | Jan 2013 | B2 |
8359080 | Diab et al. | Jan 2013 | B2 |
8364223 | Al-Ali et al. | Jan 2013 | B2 |
8364226 | Diab et al. | Jan 2013 | B2 |
8374665 | Lamego | Feb 2013 | B2 |
8385995 | Al-Ali et al. | Feb 2013 | B2 |
8385996 | Smith et al. | Feb 2013 | B2 |
8388353 | Kiani et al. | Mar 2013 | B2 |
8399822 | Al-Ali | Mar 2013 | B2 |
8401602 | Kiani | Mar 2013 | B2 |
8405608 | Al-Ali et al. | Mar 2013 | B2 |
8414499 | Al-Ali et al. | Apr 2013 | B2 |
8418524 | Al-Ali | Apr 2013 | B2 |
8423106 | Lamego et al. | Apr 2013 | B2 |
8428967 | Olsen et al. | Apr 2013 | B2 |
8430817 | Al-Ali et al. | Apr 2013 | B1 |
8437825 | Dalvi et al. | May 2013 | B2 |
8447374 | Diab | May 2013 | B2 |
8455290 | Siskavich | Jun 2013 | B2 |
8457703 | Al-Ali | Jun 2013 | B2 |
8457707 | Kiani | Jun 2013 | B2 |
8463349 | Diab et al. | Jun 2013 | B2 |
8466286 | Bellott et al. | Jun 2013 | B2 |
8471713 | Poeze et al. | Jun 2013 | B2 |
8473020 | Kiani et al. | Jun 2013 | B2 |
8483787 | Al-Ali et al. | Jul 2013 | B2 |
8489364 | Weber et al. | Jul 2013 | B2 |
8498684 | Weber et al. | Jul 2013 | B2 |
8509867 | Workman et al. | Aug 2013 | B2 |
8515509 | Bruinsma et al. | Aug 2013 | B2 |
8523781 | Al-Ali | Sep 2013 | B2 |
8529301 | Al-Ali et al. | Sep 2013 | B2 |
8532727 | Ali et al. | Sep 2013 | B2 |
8532728 | Diab et al. | Sep 2013 | B2 |
D692145 | Al-Ali et al. | Oct 2013 | S |
8547209 | Kiani et al. | Oct 2013 | B2 |
8548548 | Al-Ali | Oct 2013 | B2 |
8548550 | Al-Ali et al. | Oct 2013 | B2 |
8560032 | Al-Ali et al. | Oct 2013 | B2 |
8560034 | Diab et al. | Oct 2013 | B1 |
8570167 | Al-Ali | Oct 2013 | B2 |
8570503 | Vo et al. | Oct 2013 | B2 |
8571618 | Lamego et al. | Oct 2013 | B1 |
8571619 | Al-Ali et al. | Oct 2013 | B2 |
8577431 | Lamego et al. | Nov 2013 | B2 |
8584345 | Al-Ali et al. | Nov 2013 | B2 |
8588880 | Abdul-Hafiz et al. | Nov 2013 | B2 |
8600467 | Al-Ali et al. | Dec 2013 | B2 |
8606342 | Diab | Dec 2013 | B2 |
8626255 | Al-Ali et al. | Jan 2014 | B2 |
8630691 | Lamego et al. | Jan 2014 | B2 |
8634889 | Al-Ali et al. | Jan 2014 | B2 |
8641631 | Sierra et al. | Feb 2014 | B2 |
8652060 | Al-Ali | Feb 2014 | B2 |
7440787 | Diab | Mar 2014 | C1 |
8663107 | Kiani | Mar 2014 | B2 |
8666468 | Al-Ali | Mar 2014 | B1 |
8667967 | Al-Ali et al. | Mar 2014 | B2 |
8670811 | O'Reilly | Mar 2014 | B2 |
8670814 | Diab et al. | Mar 2014 | B2 |
8676286 | Weber et al. | Mar 2014 | B2 |
8682407 | Al-Ali | Mar 2014 | B2 |
RE44823 | Parker | Apr 2014 | E |
RE44875 | Kiani et al. | Apr 2014 | E |
8690799 | Telfort et al. | Apr 2014 | B2 |
8700112 | Kiani | Apr 2014 | B2 |
8702627 | Telfort et al. | Apr 2014 | B2 |
8706179 | Parker | Apr 2014 | B2 |
8712494 | MacNeish, III et al. | Apr 2014 | B1 |
8715206 | Telfort et al. | May 2014 | B2 |
8718735 | Lamego et al. | May 2014 | B2 |
8718737 | Diab et al. | May 2014 | B2 |
8720249 | Al-Ali | May 2014 | B2 |
8721541 | Al-Ali et al. | May 2014 | B2 |
8721542 | Al-Ali et al. | May 2014 | B2 |
8723677 | Kiani | May 2014 | B1 |
8740792 | Kiani et al. | Jun 2014 | B1 |
8754776 | Poeze et al. | Jun 2014 | B2 |
8755535 | Telfort et al. | Jun 2014 | B2 |
8755856 | Diab et al. | Jun 2014 | B2 |
8755872 | Marinow | Jun 2014 | B1 |
8761850 | Lamego | Jun 2014 | B2 |
8764671 | Kiani | Jul 2014 | B2 |
8768423 | Shakespeare et al. | Jul 2014 | B2 |
8771204 | Telfort et al. | Jul 2014 | B2 |
8777634 | Kiani et al. | Jul 2014 | B2 |
8781543 | Diab et al. | Jul 2014 | B2 |
8781544 | Al-Ali et al. | Jul 2014 | B2 |
8781549 | Al-Ali et al. | Jul 2014 | B2 |
8788003 | Schurman et al. | Jul 2014 | B2 |
8790268 | Al-Ali | Jul 2014 | B2 |
8801613 | Al-Ali et al. | Aug 2014 | B2 |
8821397 | Al-Ali et al. | Sep 2014 | B2 |
8821415 | Al-Ali et al. | Sep 2014 | B2 |
8830449 | Lamego et al. | Sep 2014 | B1 |
8831700 | Schurman et al. | Sep 2014 | B2 |
8840549 | Al-Ali et al. | Sep 2014 | B2 |
8847740 | Kiani et al. | Sep 2014 | B2 |
8849365 | Smith et al. | Sep 2014 | B2 |
8852094 | Al-Ali et al. | Oct 2014 | B2 |
8852994 | Wojtczuk et al. | Oct 2014 | B2 |
8868147 | Stippick et al. | Oct 2014 | B2 |
8868150 | Al-Ali et al. | Oct 2014 | B2 |
8870792 | Al-Ali et al. | Oct 2014 | B2 |
8886271 | Kiani et al. | Nov 2014 | B2 |
8888539 | Al-Ali et al. | Nov 2014 | B2 |
8888708 | Diab et al. | Nov 2014 | B2 |
8892180 | Weber et al. | Nov 2014 | B2 |
8897847 | Al-Ali | Nov 2014 | B2 |
8909310 | Lamego et al. | Dec 2014 | B2 |
8911377 | Al-Ali | Dec 2014 | B2 |
8912909 | Al-Ali et al. | Dec 2014 | B2 |
8920317 | Al-Ali et al. | Dec 2014 | B2 |
8921699 | Al-Ali et al. | Dec 2014 | B2 |
8922382 | Al-Ali et al. | Dec 2014 | B2 |
8929964 | Al-Ali et al. | Jan 2015 | B2 |
8942777 | Diab et al. | Jan 2015 | B2 |
8948834 | Diab et al. | Feb 2015 | B2 |
8948835 | Diab | Feb 2015 | B2 |
8965471 | Lamego | Feb 2015 | B2 |
8983564 | Al-Ali | Mar 2015 | B2 |
8989831 | Al-Ali et al. | Mar 2015 | B2 |
8996085 | Kiani et al. | Mar 2015 | B2 |
8998809 | Kiani | Apr 2015 | B2 |
9028429 | Telfort et al. | May 2015 | B2 |
9037207 | Al-Ali et al. | May 2015 | B2 |
9060721 | Reichgott et al. | Jun 2015 | B2 |
9066666 | Kiani | Jun 2015 | B2 |
9066680 | Al-Ali et al. | Jun 2015 | B1 |
9072474 | Al-Ali et al. | Jul 2015 | B2 |
9078560 | Schurman et al. | Jul 2015 | B2 |
9084569 | Weber et al. | Jul 2015 | B2 |
9095316 | Welch et al. | Aug 2015 | B2 |
9106038 | Telfort et al. | Aug 2015 | B2 |
9107625 | Telfort et al. | Aug 2015 | B2 |
9107626 | Al-Ali et al. | Aug 2015 | B2 |
9113831 | Al-Ali | Aug 2015 | B2 |
9113832 | Al-Ali | Aug 2015 | B2 |
9119595 | Lamego | Sep 2015 | B2 |
9131881 | Diab et al. | Sep 2015 | B2 |
9131882 | Al-Ali et al. | Sep 2015 | B2 |
9131883 | Al-Ali | Sep 2015 | B2 |
9131917 | Telfort et al. | Sep 2015 | B2 |
9138180 | Coverston et al. | Sep 2015 | B1 |
9138182 | Al-Ali et al. | Sep 2015 | B2 |
9138192 | Weber et al. | Sep 2015 | B2 |
9142117 | Muhsin et al. | Sep 2015 | B2 |
9153112 | Kiani et al. | Oct 2015 | B1 |
9153121 | Kiani et al. | Oct 2015 | B2 |
9161696 | Al-Ali et al. | Oct 2015 | B2 |
9161713 | Al-Ali et al. | Oct 2015 | B2 |
9167995 | Lamego et al. | Oct 2015 | B2 |
9176141 | Al-Ali et al. | Nov 2015 | B2 |
9186102 | Bruinsma et al. | Nov 2015 | B2 |
20020082488 | Al-Ali | Jun 2002 | A1 |
20020161291 | Kiani | Oct 2002 | A1 |
20030000522 | Lynn | Jan 2003 | A1 |
20030018241 | Mannheimer | Jan 2003 | A1 |
20030073890 | Hanna | Apr 2003 | A1 |
20030120164 | Nielsen | Jun 2003 | A1 |
20090247984 | Lamego et al. | Oct 2009 | A1 |
20090275844 | Al-Ali | Nov 2009 | A1 |
20100004518 | Vo et al. | Jan 2010 | A1 |
20100030040 | Poeze et al. | Feb 2010 | A1 |
20110001605 | Kiani et al. | Jan 2011 | A1 |
20110082711 | Poeze et al. | Apr 2011 | A1 |
20110105854 | Kiani et al. | May 2011 | A1 |
20110208015 | Welch et al. | Aug 2011 | A1 |
20110213212 | Al-Ali | Sep 2011 | A1 |
20110230733 | Al-Ali | Sep 2011 | A1 |
20110237911 | Lamego et al. | Sep 2011 | A1 |
20120059267 | Lamego et al. | Mar 2012 | A1 |
20120179006 | Jansen et al. | Jul 2012 | A1 |
20120209082 | Al-Ali | Aug 2012 | A1 |
20120209084 | Olsen et al. | Aug 2012 | A1 |
20120227739 | Kiani | Sep 2012 | A1 |
20120283524 | Kiani et al. | Nov 2012 | A1 |
20120296178 | Lamego et al. | Nov 2012 | A1 |
20120319816 | Al-Ali | Dec 2012 | A1 |
20120330112 | Lamego et al. | Dec 2012 | A1 |
20130023775 | Lamego et al. | Jan 2013 | A1 |
20130041591 | Lamego | Feb 2013 | A1 |
20130045685 | Kiani | Feb 2013 | A1 |
20130046204 | Lamego et al. | Feb 2013 | A1 |
20130060147 | Welch et al. | Mar 2013 | A1 |
20130096405 | Garfio | Apr 2013 | A1 |
20130096936 | Sampath et al. | Apr 2013 | A1 |
20130190581 | Al-Ali et al. | Jul 2013 | A1 |
20130197328 | Diab et al. | Aug 2013 | A1 |
20130211214 | Olsen | Aug 2013 | A1 |
20130243021 | Siskavich | Sep 2013 | A1 |
20130253334 | Al-Ali et al. | Sep 2013 | A1 |
20130296672 | O'Neil et al. | Nov 2013 | A1 |
20130317370 | Dalvi et al. | Nov 2013 | A1 |
20130324808 | Al-Ali et al. | Dec 2013 | A1 |
20130331670 | Kiani | Dec 2013 | A1 |
20130338461 | Lamego et al. | Dec 2013 | A1 |
20140034353 | Al-Ali et al. | Dec 2013 | A1 |
20140012100 | Al-Ali et al. | Jan 2014 | A1 |
20140051953 | Lamego et al. | Feb 2014 | A1 |
20140058230 | Abdul-Hafiz et al. | Feb 2014 | A1 |
20140066783 | Kiani et al. | Mar 2014 | A1 |
20140077956 | Sampath et al. | Mar 2014 | A1 |
20140081100 | Muhsin et al. | Mar 2014 | A1 |
20140081175 | Telfort | Mar 2014 | A1 |
20140094667 | Schurman et al. | Apr 2014 | A1 |
20140100434 | Diab et al. | Apr 2014 | A1 |
20140114199 | Lamego et al. | Apr 2014 | A1 |
20140120564 | Workman et al. | May 2014 | A1 |
20140121482 | Merritt et al. | May 2014 | A1 |
20140121483 | Kiani | May 2014 | A1 |
20140127137 | Bellott et al. | May 2014 | A1 |
20140129702 | Lamego et al. | May 2014 | A1 |
20140135588 | Al-Ali et al. | May 2014 | A1 |
20140142401 | Al-Ali et al. | May 2014 | A1 |
20140163344 | Al-Ali | Jun 2014 | A1 |
20140163402 | Lamego et al. | Jun 2014 | A1 |
20140166076 | Kiani et al. | Jun 2014 | A1 |
20140171763 | Diab | Jun 2014 | A1 |
20140180038 | Kiani | Jun 2014 | A1 |
20140180154 | Sierra et al. | Jun 2014 | A1 |
20140194709 | Al-Ali et al. | Jul 2014 | A1 |
20140194711 | Al-Ali | Jul 2014 | A1 |
20140194766 | Al-Ali et al. | Jul 2014 | A1 |
20140206963 | Al-Ali | Jul 2014 | A1 |
20140213864 | Abdul-Hafiz et al. | Jul 2014 | A1 |
20140243627 | Diab et al. | Aug 2014 | A1 |
20140266790 | Al-Ali et al. | Sep 2014 | A1 |
20140275808 | Poeze et al. | Sep 2014 | A1 |
20140275835 | Lamego et al. | Sep 2014 | A1 |
20140275871 | Lamego et al. | Sep 2014 | A1 |
20140275872 | Merritt et al. | Sep 2014 | A1 |
20140275881 | Lamego et al. | Sep 2014 | A1 |
20140288400 | Diab et al. | Sep 2014 | A1 |
20140303520 | Telfort et al. | Oct 2014 | A1 |
20140316228 | Blank et al. | Oct 2014 | A1 |
20140323825 | Al-Ali et al. | Oct 2014 | A1 |
20140330092 | Al-Ali et al. | Nov 2014 | A1 |
20140330098 | Merritt et al. | Nov 2014 | A1 |
20140330099 | Al-Ali et al. | Nov 2014 | A1 |
20140333440 | Kiani | Nov 2014 | A1 |
20140336481 | Shakespeare et al. | Nov 2014 | A1 |
20140343436 | Kiani | Nov 2014 | A1 |
20150018650 | Al-Ali et al. | Jan 2015 | A1 |
Number | Date | Country |
---|---|---|
3328862 | Feb 1985 | DE |
0104771 | Apr 1984 | EP |
0352923 | Jan 1990 | EP |
0645117 | Mar 1995 | EP |
0659384 | Jun 1995 | EP |
WO 8403032 | Aug 1984 | WO |
WO 9211803 | Jul 1992 | WO |
WO 9215955 | Sep 1992 | WO |
WO 9220273 | Nov 1992 | WO |
WO 9521567 | Aug 1995 | WO |
WO 9843071 | Oct 1998 | WO |
Entry |
---|
US 8,845,543, 09/2014, Diab et al. (withdrawn) |
Edward Bedrosian, The Analytic Signal Representation of Modulating Waveforms (1962). |
Boualem Boashash, Note on the Use of the Wigner Distribution for Time-Frequency Signal Analysis, IEEE on Acoustics, Speech and Signal Processing, vol. 36, No. 9 (Sep. 1988). |
Boualem Boashash, Estimating and Interpreting the Instantaneous Frequency of a Signal—Part 1: Fundamentals, Proceedings of the IEEE, vol. 80, No. 4 (Apr. 1992). |
Wukitsch, M.W., BA, et al. Pulse Oximetry: Analysis of Theory, Technology, and Practice, Journal of Clinical Monitoring, vol. 4, (1988), pp. 290-301. |
U.S. Appl. No. 90/012,403, filed Jul. 23, 2012, requesting ex parte reexamination of U.S. Pat. No. 6,263,222, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302. |
U.S. Appl. No. 90/012,409, filed Aug. 17, 2012, requesting ex parte reexamination of U.S. Pat. No. 6,699,194, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302. |
U.S. Appl. No. 90/012,463, filed Sep. 5, 2012, requesting ex parte reexamination of of U.S. Pat. No. 7,215,984, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302. |
U.S. Appl. No. 90/012,532, filed Sep. 13, 2012, requesting ex parte reexamination of U.S. Pat. No. 7,499,835, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302. |
U.S. Appl. No. 90/012,534, filed Sep. 13, 2012, requesting ex parte reexamination of U.S. Pat. No. 7,962,188, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302. |
U.S. Appl. No. 90/012,538, filed Sep. 13, 2012, requesting ex parte reexamination of U.S. Pat. No. 7,377,899, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302. |
U.S. Appl. No. 90/012,541, filed Sep. 13, 2012, requesting ex parte reexamination of U.S. Pat. No. 7,899,507, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302. |
U.S. Appl. No. 90/012,542, filed Sep. 13, 2012, requesting ex parte reexamination of U.S. Pat. No. 8,180,420, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302. |
U.S. Appl. No. 90/012,543, filed Sep. 13, 2012, requesting ex parte reexamination of U.S. Pat. No. 6,850,787, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302. |
U.S. Appl. No. 90/012,546, filed Sep. 13, 2012, requesting ex parte reexamination of U.S. Pat. No. 7,438,683, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302. |
U.S. Appl. No. 90/012,548, filed Sep. 13, 2012, requesting ex parte reexamination of U.S. Pat. No. 7,880,606, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302. |
U.S. Appl. No. 90/012,553, filed Sep. 13, 2012, requesting ex parte reexamination of U.S. Pat. No. 7,024,233, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302. |
U.S. Appl. No. 90/012,555, filed Sep. 13, 2012, requesting ex parte reexamination of U.S. Pat. No. 7,440,787, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302. |
U.S. Appl. No. 90/012,557, filed Sep. 13, 2012, requesting ex parte reexamination of U.S. Pat. No. 8,150,487, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302. |
U.S. Appl. No. 90/012,559, filed Sep. 13, 2012, requesting ex parte reexamination of U.S. Pat. No. 8,190,223, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302. |
U.S. Appl. No. 90/012,561, filed Sep. 14, 2012, requesting ex parte reexamination of U.S. Pat. No. 8,019,400, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302. |
U.S. Appl. No. 90/012,562, filed Sep. 14, 2012 requesting ex parte reexamination of U.S. Pat. No. 6,463,311, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302. |
U.S. Appl. No. 90/012,566, filed Sep. 14, 2012, requesting ex parte reexamination of U.S. Pat. No. 7,530,955, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302. |
U.S. Appl. No. 90/012,567, filed Sep. 14, 2012, requesting ex parte reexamination of U.S. Pat. No. 6,684,090, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302. |
U.S. Appl. No. 90/012,568, filed Sep. 14, 2012, requesting ex parte reexamination of U.S. Pat. No. 8,128,572, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302. |
U.S. Appl. No. 90/012,699, filed Oct. 4, 2012, requesting ex parte reexamination of U.S. Pat. No. 6,002,952, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.510 and 35 U.S.C. § 302. |
U.S. Appl. No. 95/002,183, filed Sep. 12, 2012, requesting inter partes reexamination of U.S. Pat. No. 7,530,955, including accompanying Reexam Request, claim charts, and other documentation filed under 37 C.F.R. § 1.913 and 35 U.S.C. § 311. |
Blitt, Casey D., Monitoring in Anesthesia and Critical Care Medicine, (2d ed. 1990). |
Business Wire, “Mallinckrodt Announces the Nellcor N-395 Pulse Oximeter With Oxismart XL and SatSeconds,” Oct. 7, 1999. |
Hanzo et al., “A Portable Multimedia Communicator Scheme”, Multimedia Technologies and Future Applications: Proceedings of the IEEE International Symposium (1994). |
Maciej Niedzwiecki et al. “Smoothing of Discontinuous Signals: The Competitive Approach,” IEEE Transactions on Signal Processing, vol. 43, No. 1, Jan. 1995, pp. 1-13. |
Steven W. Smith, The Scientist and Engineer's Guide to Digital Signal Processing, § 8 (1st ed. 1997). |
Declaration of Perry D. Oldham in Support of Masimo Opposition to Defendant's Motion for Summary Judgment of Invalidity and Noninfringement of U.S. Pat. No. 7,215,984, vol. 1, Doc. 556, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GMBH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Sep. 28, 2012. (Redacted). |
Declaration of Perry D. Oldham in Support of Masimo's Opposition to Defendant's Motion for Summary Judgment of Invalidity and Noninfringement of U.S. Pat. No. 7,215,984, vol. 2, Doc. 558, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GMBH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Sep. 28, 2012. (Redacted). |
Masimo Corporation's Answering Brief in Opposition to Defendant's Motion for Summary Judgment of Invalidity and Noninfringement of U.S. Pat. No. 7,215,984, Doc. 555, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GMBH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Sep. 28, 2012. (Redacted). |
Philip's Opening Brief in Support of Defendant's Motion for Summary Judgment of Invalidity and Nonnigringement of U.S. Pat. No. 7,215,984, Doc. 442, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GMBH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Aug. 21, 2012. (Redacted). |
Philip Defendant's Motion for Summary Judgment of Invalidity and Noninfringement of U.S. Pat. No. 7,215,984, Doc. 394, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GMBH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Aug. 14, 2012. |
Reply Brief in Support of Defendants' Motion for Summary Judgment of invalidity and Noninfringement of U.S. Pat. No. 7,216,984, Doc. 609, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GMBH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Oct. 26, 2012. (Redacted). |
Declaration of Gail Baura, Ph.D. in Support of Masimo's Opposition to Defendant's Motion for Summary Judgment of Invalidity of U.S. Pat. No. 7,215,984, Doc. 561, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GMBH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Sep. 28, 2012. (Redacted). |
Declaration of Gail Baura, Ph.D. in Support of Masimo's Opposition to Defendant's Motion for Summary Judgment of Invalidity of U.S. Pat. No. 5,632,272, Doc. 554, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GMBH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Sep. 28, 2012. (Redacted). |
Declaration of Perry D. Oldham in Support of Masimo Opposition to Defendant's Motion for Summary Judgment of Invalidity of U.S. Pat. No. 5,632,272, Doc. 553, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GMBH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Sep. 28, 2012. (Redacted). |
Masimo Corporation's Answering Brief in Opposition to Defendant's Motion for Summary Judgment of Invalidity and Noninfringement of U.S. Pat. No. 5,632,272, Doc. 552, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GMBH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Sep. 28, 2012. (Redacted). |
Opening Brief in Support of Defendants' Motion for Summary Judgment of Invalidity and Noninfringement of U.S. Pat. No. 5,632,272, Doc. 444, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GMBH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Aug. 21, 2012. (Redacted). |
Defendants' Motion for Summary Judgment of Invalidity and Noninfringement of U.S. Pat. No. 5,632,272, Doc. 402, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GMBH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Aug. 14, 2012. |
Reply Brief in Support of Defendants' Motion for Summary Judgment of Invalidity and Noninfringement of U.S. Pat. No. 5,632,272, Doc. 614, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GMBH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Oct. 26, 2012 (Redacted). |
Declaration of Mohammed K. Diab in Support of Masimo's Oppositions to Defendants' Motions for Summary Judgment of Invalidity and Noninfringement of U.S. Pat. Nos. 5,632,272 and 7,215,984, Doc. 563, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GMBH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Sep. 28, 2012 (Redacted). |
Declaration of Perry D. Oldham in Support of Masimo's Opposition to Defendant's Motion for Summary Judgment of Invalidity of U.S. Pat. No. 6,263,222, Doc. 550, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GMBH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Sep. 28, 2012 (Redacted). |
Masimo Corporation's Answering Brief in Opposition to Defendants' Motion for Summary Judgment of Invalidity of U.S. Pat. No. 6,263,222, Doc. 549, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GMBH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Sep. 28, 2012 (Redacted). |
Philips' Opening Brief in Support of Defendants' Motion for Summary Judgment of Invalidity of U.S. Pat. No. 6,263,222, Doc. 413, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GMBH, (District of Delaware, Case No. 1:09-cv00080 (LPS/MPT) dated Aug. 14, 2012. |
Defendants' Motion for Summary Judgment of Invalidity of U.S. Pat. No. 6,263,222, Doc. 410, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GMBH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Aug. 14, 2012. |
Reply Brief in Support of Defendants' Motion for Summary Judgment of Invalidity of U.S. Pat. No. 6,263,222, Doc. 613, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GMBH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Oct. 26, 2012 (Redacted). |
Declaration of Gail Baura, Ph.D. in Support of Masimo's Opposition to Defendant's Motion for Summary Judgment of Invalidity of U.S. Pat. No. 6,263,222, Doc. 551, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GMBH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Sep. 28, 2012. (Redacted). |
V. Ya. Volkov, “Enhancing the Reliability and Accuracy of Pulse Oximetry with a Built-In Expert System,” Biomedical Engineering, vol. 27, No. 3 (May-Jun. 1993) (translated from Russian). |
Declaration of Gail Baura, Ph.D. in Support of Masimo's Opposition to Defendant's Motion for Summary Judgment of Invalidity of U.S. Pat. No. 6,699,194, Doc. 508, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GMBH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Sep. 21, 2012. |
Opening Brief in Support of Defendants' Motion for Summary Judgment of Invalidity of U.S. Pat. No. 6,699,194, Doc. 445, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GMBH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Aug. 21, 2012. (Redacted). |
Defendants' Motion for Summary Judgment of Invalidity of U.S. Pat. No. 6,699,194, Doc. 406, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GMBH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Aug. 14, 2012. |
Reply Brief in Support of Defendants' Motion for Summary Judgment of Invalidity of U.S. Pat. No. 6,699,194, Doc. 610, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GMBH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Oct. 26, 2012. (Redacted). |
Declaration of Perry D. Oldham in Support of Masimo Opposition to Defendant's Motion for Summary Judgment of Invalidity of U.S. Pat. No. 6,699,194, Doc. 548, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GMBH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Sep. 28, 2012. (Redacted). |
Scharf, “Optimization of Portable Pulse Oximetry Through Fourier Analysis”. |
Scharf, “Pulse Oximetry Through Spectral Analysis”. |
Rusch, “Master's Thesis,” Graduate School University of South Florida, Tampa, Florida (Dec. 1994). |
Philips' Response to Masimo Corporation's Objections to the Report and Recommendation Regarding Claim Construction, Doc. 230, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GMBH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Mar. 24, 2011. |
Masimo Corporation's Objections to the Report and Recommendation Regarding Claim Construction, Doc. 219, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GMBH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Mar. 8, 2011. |
Defendants' Objections to Magistrate Judge Thynge's Report and Recommendation Regarding Claim Construction, Doc. 218, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GMBH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Mar. 7, 2011. |
Report and Recommendation Regarding Claim Construction, Doc. 210, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GMBH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Feb. 18, 2011. |
Memorandum Order Adopting Report and Recommendation Regarding Claim Construction, Doc. 319, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GMBH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Jan. 17, 2011. |
Masimo Corporation's Response to Defendants' Objections to the Report and Recommendation Regarding Claim Construction, Doc. 232, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GMBH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Mar. 24, 2011. |
V. Ya. Volkov, “Principles and Algroithms for Determining Blood Oxygenation Level by Pulse Oximetry,” Biomedical Engineering, vol. 27, No. 1 (Jan.-Feb. 1993) (translated from Russian). |
Supplemental Expert Report of Dr. Robert Stone Regarding the invalidity of Masimo's Patents-in-Suit (U.S. Pat. No. 5,632,272, U.S. Pat. No. 6,263,222, U.S. Pat. No. 7,215,984, and U.S. Pat. No. 6,699,194, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GMBH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Mar. 18, 2012. |
Appendixes for Expert Report of Dr. Robert Stone Regarding the invalidity of Masimo's Patents-in-Suit (U.S. Pat. No. 5,632,272, U.S. Pat. No. 6,263,222, U.S. Pat. No. 7,215,984, and U.S. Pat. No. 6,699,194, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GMBH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Mar. 7, 2012. |
Expert Report of Dr. Robert Stone Regarding the invalidity of Masimo's Patents-in-Suit (U.S. Pat. No. 5,632,272, U.S. Pat. No. 6,263,222, U.S. Pat. No. 7,215,984, and U.S. Pat. No. 6,699,194, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GMBH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Mar. 7, 2012. |
Revised Expert Report of Dr. Robert Stone Regarding the invalidity of Masimo's Patents-in-Suit (U.S. Pat. No. 5,632,272, U.S. Pat. No. 6,263,222, U.S. Pat. No. 7,215,984, and U.S. Pat. No. 6,699,194, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GMBH, (District of Delaware, Case No. 1:09-cv-00080 (LPS/MPT) dated Mar. 7, 2012. |
Wukitsch, et al., “Knowing Your Monitoring Equipment,” Journal of Clinical Monitoring, vol. 4, No. 4 (Oct. 1998). |
Second Amended Complaint for Patent Infringement, Doc. 42, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GMBH, (District of Delaware, Case No. 1:11-cv-00742 (LPS/MPT) dated Apr. 25, 2012. |
Masimo's Answer to Philips' Counterclaims, Doc. 28, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GMBH, (District of Delaware, Case No. 1:11-cv-00742 (LPS/MPT) dated Dec. 30, 2011. |
Defendants' Answer and Philips Electronics North America Corp.'s Counterclaims to Masimo's First Amended Complaint, Doc. 11, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GMBH, (District of Delaware, Case No. 1:11-cv-00742 (LPS/MPT) dated Nov. 7, 2011. |
Masimo's Answer to Philips' Counterclaims to Masimo's Second Amended Complaint, Doc. 358, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GMBH, (District of Delaware, Case No. 1:11-cv-00742 (LPS/MPT) dated Jun. 4, 2012. |
Defendants' Answer and Philips Electronics North America Corp.'s Counterclaims to Masimo's Second Amended Complaint, Doc. 43, Masimo Corporation v. Philips Electronics North America Corporation and Philips Medizin Systeme Böblingen GMBH, (District of Delaware, Case No. 1:11-cv-00742 (LPS/MPT) dated May 11, 2012. |
Number | Date | Country | |
---|---|---|---|
20150201874 A1 | Jul 2015 | US |
Number | Date | Country | |
---|---|---|---|
60430834 | Dec 2002 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 13896731 | May 2013 | US |
Child | 14609841 | US | |
Parent | 12248868 | Oct 2008 | US |
Child | 13896731 | US | |
Parent | 11288812 | Nov 2005 | US |
Child | 12248868 | US | |
Parent | 10727348 | Dec 2003 | US |
Child | 11288812 | US |